Giapreza
- Generic Name: angiotensin ii injection for infusion
- Brand Name: Giapreza
Giapreza (Angiotensin II Injection for Infusion) side effects drug center
Giapreza Side Effects Center
What Is Giapreza?
Giapreza (angiotensin II) is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.
What Are Side Effects of Giapreza?
Common side effects of Giapreza include:
- blood clots,
- low platelet count (thrombocytopenia),
- fast heart rate,
- fungal infection,
- delirium,
- high levels of acid on the blood (acidosis),
- high blood sugar (hyperglycemia), and
- lack of blood flow to extremities
Dosage for Giapreza?
The starting dose of Giapreza is 20 nanograms (ng)/kg/min administered intravenously. The dose is adjusted as frequently as every 5 minutes by increments of up to 15 ng/kg/min as needed.
What Drugs, Substances, or Supplements Interact with Giapreza?
Giapreza may interact with angiotensin converting enzyme (ACE) inhibitors and angiotensin II blockers (ARBs). Tell your doctor all medications and supplements you use.
Giapreza During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Giapreza; it is unknown if it would affect a fetus. It is unknown if Giapreza passes into breast milk. Consult your doctor before breastfeeding.
Additional Information
Our Giapreza (angiotensin II) Injection for Intravenous Infusion Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Giapreza Professional Information
SIDE EFFECTS
Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
ATHOS-3
The safety of GIAPREZA was evaluated in ATHOS-3 [see WARNINGS AND PRECAUTIONS] . Patients in ATHOS-3 were receiving other vasopressors in addition to GIAPREZA or placebo, which were titrated to effect on mean arterial pressure (MAP).
Table 2: Adverse Reactions Occurring in ≥ 4% of Patients Treated with GIAPREZA and ≥ 1.5% More Often than in Placebo-treated Patients in ATHOS-3
| Adverse Event | GIAPREZA N=163 | Placebo N=158 |
| Thromboembolic events* | 21 (12.9%) | 8 (5.1%) |
| Deep vein thrombosis | 7 (4.3%) | 0 (0.0%) |
| Thrombocytopenia | 16 (9.8%) | 11 (7.0%) |
| Tachycardia | 14 (8.6%) | 9 (5.7%) |
| Fungal infection | 10 (6.1%) | 2 (1.3%) |
| Delirium | 9 (5.5%) | 1 (0.6%) |
| Acidosis | 9 (5.5%) | 1 (0.6%) |
| Hyperglycemia | 7 (4.3%) | 4 (2.5%) |
| Peripheral ischemia | 7 (4.3%) | 4 (2.5%) |
| * Including arterial and venous thrombotic events | ||
Read the entire FDA prescribing information for Giapreza (Angiotensin II Injection for Infusion)
&Copy; Giapreza Patient Information is supplied by Cerner Multum, Inc. and Giapreza Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.